Clinical pharmacology study to investigate the food effect on pharmacokinetics of TAS-102.

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221443

Enrollment

Registered

2011-04-26

Start date

2011-04-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with solid tumor

Interventions

investigational material(s) Generic name etc : TAS-102 INN of investigational material : Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Signed, written informed consent. 2) Histologically or cytologically confirmed solid tumor. 3) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion criteria: 1) Patients with gastric cancer or stomach excised

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics	—

Secondary

Measure	Time frame
Safety, Efficacy CTCAE (ver.4.0), RECIST (ver.1.1)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026